Journal article
High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study
Gynecologic Oncology, Vol.146(2), pp.247-253
08/2017
DOI: 10.1016/j.ygyno.2017.05.017
PMCID: PMC5526627
PMID: 28532857
Abstract
Gynecologic Oncology Group (GOG) 177 demonstrated that addition of paclitaxel to a backbone of adriamycin/cisplatin improves overall survival (OS) and progression-free survival (PFS) for patients with advanced or recurrent endometrial cancer. Using patient specimens from GOG-177, our objective was to identify potential mechanisms underlying the improved clinical response to taxanes. Stathmin (STMN1) is a recognized poor prognostic marker in endometrial cancer that functions as a microtubule depolymerizing protein, allowing cells to transit rapidly through mitosis. Therefore, we hypothesized that one possible mechanism underlying the beneficial effects of paclitaxel could be to counter the impact of stathmin. We analyzed the expression of stathmin by immunohistochemistry (IHC) in 69 specimens from patients enrolled on GOG-177. We also determined the correlation between stathmin mRNA expression and clinical outcomes in The Cancer Genome Atlas (TCGA) dataset for endometrial cancer. We first established that stathmin expression was significantly associated with shorter PFS and OS for all analyzed cases in both GOG-177 and TCGA. However, subgroup analysis from GOG-177 revealed that high stathmin correlated with poor PFS and OS particularly in patients who received adriamycin/cisplatin only. In contrast, there was no statistically significant association between stathmin expression and OS or PFS in patients treated with paclitaxel/adriamycin/cisplatin. Our findings demonstrate that high stathmin expression is a poor prognostic marker in endometrial cancer. Paclitaxel may help to negate the impact of stathmin overexpression when treating high risk endometrial cancer cases. •This study sought to define markers of response on GOG Study 177.•Addition of paclitaxel to adriamycin/cisplatin regimen improves clinical outcomes.•High stathmin is associated with poor outcomes on the adriamycin/cisplatin arm.•Paclitaxel may negate the effects of stathmin overexpression.
Details
- Title: Subtitle
- High stathmin expression is a marker for poor clinical outcome in endometrial cancer: An NRG oncology group/gynecologic oncology group study
- Creators
- Henry D Reyes - Department of Obstetrics & Gynecology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USAJeffrey Miecznikowski - Department of Biostatistics, SUNY University at Buffalo, Buffalo, NY, USAJesus Gonzalez-Bosquet - Department of Obstetrics & Gynecology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USAEric J Devor - Department of Obstetrics & Gynecology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USAYuping Zhang - Department of Obstetrics & Gynecology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USAKristina W Thiel - Department of Obstetrics & Gynecology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USAMegan I Samuelson - Department of Pathology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USAMegan McDonald - Department of Obstetrics & Gynecology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USAJean-Marie Stephan - Department of Obstetrics & Gynecology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USAParviz Hanjani - Department of Gynecologic Oncology, Hanjani Institute for Gynecologic Oncology, Abington Memorial Hospital, Abington, PA, USASaketh Guntupalli - Department of Obstetrics & Gynecology, University of Colorado – Denver, Aurora, CO, USAKrishnansu S Tewari - Division of Gynecologic Oncology, University of California, Irvine Medical Center, Orange, CA, USAFloor Backes - Department/Division of Obstetrics & Gynecology, Ohio State University Medical Center, Columbus, OH, USANilsa Ramirez - Department of Pathology, The Research Institute at Nationwide Children's Hospital, Columbus, OH, USAGini F Fleming - Section of Medical Oncology, University of Chicago, Chicago, IL, USAVirginia Filiaci - Biostatistics & Data Center, NRG Oncology/Gynecologic Oncology Group, Roswell Park Cancer Institute, Buffalo, NY, USAMichael J Birrer - Department of Hematology/Oncology, Massachusetts General Hospital, Boston, MA, USAKimberly K Leslie - Department of Obstetrics & Gynecology, The Holden Comprehensive Cancer Center, University of Iowa, Iowa City, IA, USA
- Resource Type
- Journal article
- Publication Details
- Gynecologic Oncology, Vol.146(2), pp.247-253
- DOI
- 10.1016/j.ygyno.2017.05.017
- PMID
- 28532857
- PMCID
- PMC5526627
- NLM abbreviation
- Gynecol Oncol
- ISSN
- 0090-8258
- eISSN
- 1095-6859
- Publisher
- Elsevier Inc
- Grant note
- R01CA99908; R01CA184101; K12-HD063117 / NIH (http://dx.doi.org/10.13039/100000002) 1U10 CA180822; U10CA180868 / National Cancer Institute (http://dx.doi.org/10.13039/100000054) Department of Obstetrics and Gynecology Research Development Fund
- Language
- English
- Date published
- 08/2017
- Academic Unit
- Pathology; Obstetrics and Gynecology
- Record Identifier
- 9983931369402771
Metrics
54 Record Views